MMMayumi Mukai

Mayumi Mukai

*This is an algorithmically generated author record based on publicly available information.

Mayumi Mukai has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exposure‐Response Analysis for Mogamulizumab in Adults With Cutaneous T‐Cell Lymphoma

    by Mayumi Mukai, Diane Mould, Hiroshi Maeda, Kazuya Narushima, Douglas Greene

    Mogamulizumab is a humanized monoclonal antibody against C‐C chemokine receptor 4 approved in the United States for the treatment of patients with relapsed/refractory mycosis fungoides or Sézary syndrome, the most common forms of cutaneous T‐cell lymphoma (CTCL). The exposure‐response relationships for efficacy (progression‐free survival [PFS] and overall response rate [ORR]) and safety (the 5 most common treatment‐related adverse events by Medical Dictionary for Regulatory Activities [MedDRA] System Organ Class) for 184 patients with CTCL treated with mogamulizumab in a large, registrational clinical trial. Exposure metrics were area under the serum mogamulizumab concentration‐time curve over the dose interval at steady state (AUCss) and minimum serum mogamulizumab concentration after the first dose (Cmin,1st). PFS by investigator assessment, the primary efficacy objective, and PFS and ORR by independent review were not correlated with exposure metrics; however, there was a statistically significant positive relationship between a secondary objective, ORR by investigator assessment, and AUCss (P = .0168). The frequency of treatment‐related adverse events was not related to exposure metrics (Cmin,1st or AUCss) for any of the MedDRA System Organ Classes examined. Of the covariates that were found to have a statistically significantly effect on the population PK model (ie, albumin, aspartate aminotransferase, body surface area, mild to moderate hepatic impairment, and sex), none was found to impact efficacy or safety, indicating that there is no need to modify dose on the basis of these parameters.


  • Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T‐Cell Lymphoma or Adult T‐Cell Lymphoma

    by Mayumi Mukai, Hiroshi Maeda, Kazuya Narushima, Diane R. Mould, Douglas Greene

    Cutaneous T‐cell lymphoma (CTCL) and adult T‐cell leukemia/lymphoma (ATL) are rare non‐Hodgkin lymphomas commonly expressing C‐C chemokine receptor 4 (CCR4). Mogamulizumab is a humanized monoclonal antibody against CCR4 approved in the United States for the treatment of patients with relapsed/refractory mycosis fungoides or Sézary syndrome, the most common forms of CTCL. Pharmacokinetic (PK) and clinical study data from 444 adult patients with ATL or CTCL collected during 6 clinical trials of mogamulizumab were used to construct a population PK model, which was best described by a 2‐compartment model with linear clearance. Albumin, aspartate aminotransferase, mild‐to‐moderate hepatic impairment, and sex were statistically significant predictors of clearance; albumin was also a statistically significant predictor of peripheral volume of distribution; and body surface area was a statistically significant predictor for central volume of distribution. None of the other covariates—for example, age, body weight, body mass index, bilirubin, creatinine clearance, disease type (ATL and CTCL), ATL subtype (acute, lymphoma, and chronic), CTCL subtype (mycosis fungoides and Sézary syndrome), CCR4 expression (status or degree), race (Japanese and non‐Japanese), renal impairment (normal, mild, moderate, and severe), or performance status—had a statistically significant impact. Performance of the final population PK model was acceptable. This model will be valuable for guiding further studies of mogamulizumab.